Drugs / BQ-788
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT02442466 | May 2011 → May 2012 | melanoma | MelCure SA | Terminated | No outcome recorded Stop: Enrollment |
| Phase 12 trials | ||||||
| Phase 1 | NCT03679780 | Oct 2018 → Jul 2023 | cardiovascular disorder | The University of Texas at Arlington | Completed | No outcome recorded |
| Phase 1 | NCT00427232 | May 2003 → Aug 2006 | coronary artery disorder | Medical University of Vienna | Completed | No outcome recorded |
| Phase not applicable4 trials · 1 met primary | ||||||
| — | NCT04907838 | May 2018 → Jul 2021 | type 2 diabetes mellitus | University of Southern Denmark | Unknown | No outcome recorded |
| — | NCT02062346 | Aug 2016 → Jan 2020 | vasculitis | University of Edinburgh | Completed | Met primary |
| — | NCT02086253 | Feb → May 2014 | — | University Hospital, Rouen | Completed | No outcome recorded |
| — | NCT00745693 | Mar → May 2008 | coronary artery disorder | University of Edinburgh | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2008-01-06 | 7 Hills Pharma, LLC | Results Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy 7hillspharma.com ↗
In mice, ETBR neutralization by BQ-788 increased T cell homing to tumors; this homing required ICAM-1 and enabled tumor response to otherwise ineffective immunotherapy in vivo without changes in systemic antitumor immune response. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2008-01-06 | 7 Hills Pharma, LLC | Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy 7hillspharma.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BQ788 | “Intravenous infusion of BQ123 1000nmol/min and BQ788 300nmol/min” NCT02062346 ↗ |
| Known as | American Peptides - 88-2-55 (BQ-788) | “American Peptides - 88-2-55 (BQ-788)” NCT00745693 ↗ |
| Action | Inhibit | “the ET-B receptor blocker BQ-788” PMID 19414437 ↗ May 2009 |
| Route | Other | “Intracoronary infusion (30 minutes) of the ET-A receptor blocker BQ-123 (40 nmol/min, group A, n = 13) alone or with the ET-B receptor blocker BQ-788” PMID 19414437 ↗ May 2009 |
| Target | EDNRB | “an endothelin receptor B (EDNRB) antagonist” PMID 26330458 ↗ Sep 2015 |